You searched for: Iconovo
Iconovo reports Q2
Iconovo focuses on commercialization
Iconovo is currently undergoing a strategic reorganization in connection with the company's five inhaler platforms reaching full development. In an interview...
Iconovo raises capital and reorganizes
Iconovo is raising capital of SEK 36,6 million and is simultaneously restructuring the organization with the aim of strengthening the commercial focus now...
BioStock Investor Pitch: Iconovo
The subscription period has now begun for Iconovo's rights issue. The issue will finance continued partnership discussions around ICOpre, the development of an intranasal semaglutide product...
Iconovo and Lonza launch collaboration to strengthen obesity projects
Iconovo enters into a strategic partnership with Lonza to take the next step in the company's obesity project. By contributing...
Capital injection strengthens Iconovo
Iconovo is raising capital to continue driving its inhalation projects forward. The goal is, among other things, to secure licensing agreements...
Inhalation specialists Iconovo raises capital
An intranasal obesity treatment under development, a generic challenger to the asthma product Symbicort and talks with potential partners are on the agenda...
Future obesity treatment: Iconovo invests in intranasal semaglutide
Iconovo has initiated the development of an intranasally inhaled and reformulated version of semaglutide for the treatment of obesity. By...
BioStock Global Forum 2024
On May 29-30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing...
Full focus on financing and new CEO for Arcede
Preparations for Phase I are largely complete. What Arcede Pharma now needs to solve is financing for upcoming...
Iconovo begins development of inhaled obesity treatment
Iconovo has filed a broad patent application for inhaled GLP-1 receptor agonists, which are used for the treatment of obesity and type 2 diabetes....
New results confirmed for Arcede Pharma
Preclinical studies at the Università degli studi di Roma Tor Vergata confirm that the drug candidate RCD405 has both airway dilating and anti-inflammatory...